Proapoptotic CD95L levels in normal human serum and sera of breast cancer patients
- 199 Downloads
The CD95 pathway is a critical apoptotic pathway used by immune cells to avoid cancer development. CD95 ligand (CD95L) is found in several forms, as a cell membrane-associated form, a soluble metalloprotease-cleaved form, and a soluble but membrane-bound CD95L released on cell-derived exosomes. In this study, we used a cell-based assay to evaluate the activity of proapoptotic CD95L in sera from healthy individuals and breast cancer patients. We confirmed that our cell-based assay using Jurkat cells was sensitive to the presence of proapoptotic CD95L in serum, and apoptosis induction by mechanisms other than CD95 was discriminated using apoptosis-resistant Jurkat subclones. Our results indicated a proapoptotic potential of normal serum that involved CD95L. Sera from breast cancer patients exhibited significantly decreased apoptosis induction, due to increased CD95 receptor levels compared with healthy women. Apoptotic potential tended to decrease as the Breast Imaging Reporting and Data System grade increased, and we observed restoration of proapoptotic potential after tumor removal. The CD95L in serum responsible for apoptotic induction was associated with high-molecular-weight particles, perhaps with exosomes. The sera of healthy individuals generally contain a proapoptotic environment, and this property is mainly maintained by the presence of CD95L. Furthermore, measurement of CD95L-mediated apoptosis induction by sera could be a useful parameter to be evaluated during cancer development and therapeutic response.
KeywordsApoptosis Breast cancer CD95L Cell-based assay Serum
VOA is grateful for the scholarship obtained from CONACyT Mexico. We are very grateful to Leticia Ramos-Zavala for her efficient technical support in the laboratory. This work was supported by the Fondo de Investigación en Salud, IMSS (grants FIS/IMSS/PROT/G10/874 to AAL and FIS/IMSS/PROT/G09/744 to LFJS).
Conflicts of interest
- 10.Monleon I, Martinez-Lorenzo MJ, Monteagudo L, Lasierra P, Taules M, Iturralde M, et al. Differential secretion of Fas ligand- or APO2 ligand/TNF-related apoptosis-inducing ligand-carrying microvesicles during activation-induced death of human T cells. J Immunol. 2001;167(12):6736–44.CrossRefPubMedGoogle Scholar
- 11.Kim JW, Wieckowski E, Taylor DD, Reichert TE, Watkins S, Whiteside TL. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res: Off J Am Assoc Cancer Res. 2005;11(3):1010–20.Google Scholar
- 21.Juo P, Woo MS, Kuo CJ, Signorelli P, Biemann HP, Hannun YA, et al. FADD is required for multiple signaling events downstream of the receptor Fas. Cell Growth Diff: Molec Biol J Am Assoc Cancer Res. 1999;10(12):797–804.Google Scholar
- 28.Mizutani Y, Hongo F, Sato N, Ogawa O, Yoshida O, Miki T. Significance of serum soluble Fas ligand in patients with bladder carcinoma. Cancer. 2001;45(3):199–204.Google Scholar
- 30.Koncz G, Hancz A, Chakrabandhu K, Gogolak P, Kerekes K, Rajnavolgyi E, et al. Vesicles released by activated T cells induce both Fas-mediated RIP-dependent apoptotic and Fas-independent nonapoptotic cell deaths. J Immunol. 2012;189(6):2815–23. doi: 10.4049/jimmunol.1102827.CrossRefPubMedGoogle Scholar
- 37.Holm AM, Tjonnfjord G, Yndestad A, Beiske K, Muller F, Aukrust P, et al. Polyclonal expansion of large granular lymphocytes in common variable immunodeficiency - association with neutropenia. Clin Exp Immunol. 2006;144(3):418–24. doi: 10.1111/j.1365-2249.2006.03086.x.CrossRefPubMedPubMedCentralGoogle Scholar
- 38.Nabipour I, Kalantarhormozi M, Assadi M, Jafari SM, Gharibi M, Ahmadi E, et al. Influence of levothyroxine treatment on serum levels of soluble Fas (CD95) and Fas Ligand (CD95L) in chronic autoimmune hypothyroidism. Endocrine. 2010;38(3):406–11. doi: 10.1007/s12020-010-9401-x.CrossRefPubMedGoogle Scholar
- 47.Aguilar-Lemarroy A, Romero-Ramos JE, Olimon-Andalon V, Hernandez-Flores G, Lerma-Diaz JM, Ortiz-Lazareno PC, et al. Apoptosis induction in Jurkat cells and sCD95 levels in women’s sera are related with the risk of developing cervical cancer. BMC Cancer. 2008;8:99. doi: 10.1186/1471-2407-8-99.CrossRefPubMedPubMedCentralGoogle Scholar